Showing results (151-160 of 161) with videos related to

Sort By:
Pageof 17
BMJ (Clinical Research Ed.)|May 23, 1992
Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramineD J Betteridge, D Bhatnager, R F Bing, et al.
Diabetologia|February 1, 2007
Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS)M Raikou, A McGuire, H M Colhoun, et al.
Postgraduate Medical Journal|May 1, 1993
Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia AssociationD J Betteridge, P M Dodson, P N Durrington, et al.
The American Journal of Medicine|June 6, 1994
Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemiaD J Betteridge, P N Durrington, G J Fairhurst, et al.
Heart (British Cardiac Society)|November 18, 2004
Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemiaH A W Neil, V Seagroatt, D J Betteridge, et al.
Nature Genetics|February 2, 2000
LMNA, encoding lamin A/C, is mutated in partial lipodystrophyS Shackleton, D J Lloyd, S N Jackson, et al.
Diabetologia|October 31, 2008
Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS)V Charlton-Menys, D J Betteridge, H Colhoun, et al.
The Cochrane Database of Systematic Reviews|October 21, 2004
Omega 3 fatty acids for prevention and treatment of cardiovascular diseaseL Hooper, R L Thompson, R A Harrison, et al.
Journal of Medical Genetics|December 5, 2006
Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease riskS E Humphries, R A Whittall, C S Hubbart, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|December 21, 2010
Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1)M K Rutter, H R Prais, V Charlton-Menys, et al.
Pageof 17